STAT+: Novo’s subscription model raises questions about pharma-telehealth tie-ups
Why it matters: Novo Nordisk's new subscription model could alter drug access for patients using telehealth providers.
- Novo Nordisk announced it will sell its obesity drugs at a lower cash price to patients subscribing through certain telehealth providers.
- The new subscription plan aims to make Novo Nordisk's obesity medications more accessible while integrating telehealth services into the purchasing process.
- The pharma-telehealth tie-up is prompting discussions regarding the evolving landscape of drug distribution and patient access models.
Novo Nordisk is introducing a subscription model for its obesity drugs, offering them at a reduced cash price to patients who enroll through specific telehealth providers. This move by Novo Nordisk is sparking debate and raising questions about the growing integration and potential implications of pharmaceutical companies partnering with telehealth services.
